Top

Published in:

Open Access 01-12-2022 | Guillain-Barré Syndrome | Letter to the editor

Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy

Authors: Maria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, Christos Moschovos, Eleni Bakola, Aikaterini Foska, Konstantinos Melanis, Elisabeth Andreadou, Konstantinos Voumvourakis, Matilda Papathanasiou, Eleni Boutati, Georgios Tsivgoulis

Published in: Neurological Research and Practice | Issue 1/2022

Abstract

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.

Walter, A., & Kraemer, M. (2021). A neurologist’s rhombencephalitis after comirnaty vaccination: A change of perspective. Neurological Research and Practice, 3(1), 56. https://doi.org/10.1186/s42466-021-00156-7CrossRefPubMedPubMedCentral

Torabi, A., Mohammadbagheri, E., Akbari Dilmaghani, N., Bayat, A. H., Fathi, M., Vakili, K., et al. (2020). Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia. ACS Chemical Neuroscience, 11(13), 1909–1913. https://doi.org/10.1021/acschemneuro.0c00249CrossRefPubMed

Thakur, K. T., Epstein, S., Bilski, A., Balbi, A., Boehme, A. K., Brannagan, T. H., et al. (2021). Neurologic safety monitoring of COVID-19 vaccines: Lessons from the past to inform the present. Neurology, 97(16), 767–775. https://doi.org/10.1212/wnl.0000000000012703CrossRefPubMedPubMedCentral

Lotan, I., Romanow, G., & Levy, M. (2021). Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Mult Scler Relat Disord., 55, 103189. https://doi.org/10.1016/j.msard.2021.103189CrossRefPubMedPubMedCentral

Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., et al. (2021). Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine, 27(12), 2144–2153. https://doi.org/10.1038/s41591-021-01556-7CrossRefPubMedPubMedCentral

Román, G. C., Gracia, F., Torres, A., Palacios, A., Gracia, K., & Harris, D. (2021). Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Frontiers in Immunology, 12, 653786. https://doi.org/10.3389/fimmu.2021.653786CrossRefPubMedPubMedCentral

Palaiodimou, L., Stefanou, M. I., Katsanos, A. H., Fragkou, P. C., Papadopoulou, M., Moschovos, C., et al. (2021). Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. European Journal of Neurology, 28(10), 3517–3529. https://doi.org/10.1111/ene.14860CrossRefPubMed

Khan, E., Shrestha, A. K., Colantonio, M. A., Liberio, R. N., & Sriwastava, S. (2021). Acute transverse myelitis following SARS-CoV-2 vaccination: A case report and review of literature. Journal of Neurology. https://doi.org/10.1007/s00415-021-10785-2CrossRefPubMedPubMedCentral

Garg, R. K., & Paliwal, V. K. (2021). Spectrum of neurological complications following COVID-19 vaccination. Neurological Sciences. https://doi.org/10.1007/s10072-021-05662-9CrossRefPubMedPubMedCentral

10.

Pagenkopf, C., & Südmeyer, M. (2021). A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. Journal of Neuroimmunology, 358, 577606. https://doi.org/10.1016/j.jneuroim.2021.577606CrossRefPubMedPubMedCentral

11.

Introna, A., Caputo, F., Santoro, C., Guerra, T., Ucci, M., Mezzapesa, D. M., et al. (2021). Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clinical Neurology and Neurosurgery, 208, 106887. https://doi.org/10.1016/j.clineuro.2021.106887CrossRefPubMedPubMedCentral

12.

Rossetti, A., Gheihman, G., O’Hare, M., & Kosowsky, J. M. (2021). Guillain-Barré syndrome presenting as facial diplegia after COVID-19 vaccination: A case report. Journal of Emergency Medicine, 61(6), e141–e145. https://doi.org/10.1016/j.jemermed.2021.07.062CrossRef

13.

Finsterer, J. (2021). Exacerbating Guillain-Barré syndrome eight days after vector-based COVID-19 vaccination. Case Reports in Infectious Diseases, 2021, 3619131. https://doi.org/10.1155/2021/3619131CrossRefPubMedPubMedCentral

14.

McKean, N., & Chircop, C. (2021). Guillain-Barré syndrome after COVID-19 vaccination. BML Case Reports, 14, 7. https://doi.org/10.1136/bcr-2021-244125CrossRef

15.

Hasan, T., Khan, M., Khan, F., & Hamza, G. (2021). Case of Guillain-Barré syndrome following COVID-19 vaccine. BML Case Reports, 14, 6. https://doi.org/10.1136/bcr-2021-243629CrossRef

16.

Woo, E. J., Mba-Jonas, A., Dimova, R. B., Alimchandani, M., Zinderman, C. E., & Nair, N. (2021). Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA, 326(16), 1606–1613. https://doi.org/10.1001/jama.2021.16496CrossRefPubMed

17.

Heinz, F. X., & Stiasny, K. (2021). Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines, 6(1), 104. https://doi.org/10.1038/s41541-021-00369-6CrossRefPubMedPubMedCentral

18.

Schardt, J. S., Pornnoppadol, G., Desai, A. A., Park, K. S., Zupancic, J. M., Makowski, E. K., et al. (2021). Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening. Science and Reports, 11, 20738. https://doi.org/10.1038/s41598-021-99401-xCrossRef

19.

Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., & Spudich, S. (2020). Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurology, 77(8), 1018–1027. https://doi.org/10.1001/jamaneurol.2020.2065CrossRefPubMedPubMedCentral

20.

Moutal, A., Martin, L. F., Boinon, L., Gomez, K., Ran, D., Zhou, Y., et al. (2020). SARS-CoV-2 Spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. bioRxiv. https://doi.org/10.1101/2020.07.17.209288CrossRefPubMedPubMedCentral

21.

Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., et al. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 370(6518), 856–860.CrossRef

22.

Mayi, B. S., Leibowitz, J. A., Woods, A. T., Ammon, K. A., Liu, A. E., & Raja, A. (2021). The role of neuropilin-1 in COVID-19. PLoS Pathogens., 17(1), e1009153.CrossRef

23.

Davies, J., Randeva, H. S., Chatha, K., Hall, M., Spandidos, D. A., Karteris, E., et al. (2020). Neuropilin-1 as a new potential SARS-CoV-2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID-19. Molecular Medicine Reports, 22(5), 4221–4226. https://doi.org/10.3892/mmr.2020.11510CrossRefPubMedPubMedCentral

24.

Daly, J. L., Simonetti, B., Klein, K., Chen, K.-E., Williamson, M. K., Antón-Plágaro, C., et al. (2020). Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science, 370(6518), 861–865.CrossRef

25.

Solomon, B. D., Mueller, C., Chae, W. J., Alabanza, L. M., & Bynoe, M. S. (2011). Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 108(5), 2040–2045. https://doi.org/10.1073/pnas.1008721108CrossRefPubMedPubMedCentral

26.

Wang, Y., Cao, Y., Mangalam, A. K., Guo, Y., LaFrance-Corey, R. G., Gamez, J. D., et al. (2016). Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells. Journal of Cell Science, 129(20), 3911–3921. https://doi.org/10.1242/jcs.190702CrossRefPubMedPubMedCentral

27.

Siri, M., Dastghaib, S., Zamani, M., Rahmani-Kukia, N., Geraylow, K. R., Fakher, S., et al. (2021). Autophagy, unfolded protein response, and neuropilin-1 cross-talk in SARS-CoV-2 infection: What can be learned from other coronaviruses. International Journal of Molecular Sciences, 22, 11. https://doi.org/10.3390/ijms22115992CrossRef

28.

Rodriguez-Perez, A. I., Labandeira, C. M., Pedrosa, M. A., Valenzuela, R., Suarez-Quintanilla, J. A., Cortes-Ayaso, M., et al. (2021). Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. Journal of Autoimmunity, 122, 102683. https://doi.org/10.1016/j.jaut.2021.102683CrossRefPubMedPubMedCentral

Title: Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
Authors: Maria Ioanna Stefanou
Eleni Karachaliou
Maria Chondrogianni
Christos Moschovos
Eleni Bakola
Aikaterini Foska
Konstantinos Melanis
Elisabeth Andreadou
Konstantinos Voumvourakis
Matilda Papathanasiou
Eleni Boutati
Georgios Tsivgoulis
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Guillain-Barré Syndrome
Magnetic Resonance Imaging
Magnetic Resonance Imaging
COVID-19 Vaccination
Vaccination
SARS-CoV-2
Published in: Neurological Research and Practice / Issue 1/2022
Electronic ISSN: 2524-3489
DOI: https://doi.org/10.1186/s42466-022-00172-1

At a glance: The STEP trials

Springer Medicine

Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Intravenous thrombolysis for acute ischemic stroke associated with known left ventricular thrombus: safe or not?

Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry

Prognostic markers of post-stroke depression (PROMoSD): study protocol of a prospective single-center observational study on raphe hypoechogenicity as a predictor of post-stroke depression

The gut-brain axis in ischemic stroke: its relevance in pathology and as a therapeutic target

Recovery of intracranial stenoses in varicella zoster virus vasculitis after long-term treatment with valacyclovir and prednisolone

Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication